Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus Infection

Clinical Infectious Diseases

Volumn 37, Issue 11, 2003, Pages 1434-1440

  Hagmann, Stefan ^a,c   Chung, May ^a   Rochford, Gemma ^a   Jani, Mudra ^a   Trinh Shevrin, Chau ^a   Sitnitskaya, Yekaterina ^a,d   Neumann, Avidan U ^b   Pollack, Henry ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG INDICATION; FEMALE; HEPATITIS B; HUMAN; MALE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0344688313     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378739     Document Type: Article

References (26)

1. Lee WM. Hepatitis B infection. N Engl J Med 1997; 337:1733-45.
2. Hsieh CC, Tzonou A, Zavitsanosx X, Kaklamani E, Lan SJ, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. Am J Epidemiol 1992; 136: 1115-21.
3. Lok ASF, McMahon BJ. Chronic hepatitis B. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2001; 34:1225-41.
4. Torre D, Tambini R. Interferon-α therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23:131-7.
5. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis 1996; 174:16-25.
6. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
7. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial for lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-13.
8. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000; 44:590-7.
9. Kocak N, Saltik IN, Oezen H, et al. Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology 2000; 31: 545-6.
10. Abe A, Inoue K, Tanaka T, et al. Quantification of hepatitis B virus genomic DNA by real-time detection PCR. J Clin Microbiol 1999; 37: 2899-903.
11. Vet JA, Majithia AR, Marras S, et al. Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc Natl Acad Sci USA 1999; 96:6394-9.
12. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford, London: Blackwell Sciences, 2002.
13. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 1757-62.
14. Tsiang M, Roodney JF, Toole JJ, et al. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29:1863-9.
15. Lewin SR, Ribeiro RM, Walters T, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34:1012-20.
16. Buti M, Sanchez F, Ctrina M, et al. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B. J Infect Dis 2001; 183:1277-80.
17. Puchhammer-Stöckl E, Mandl CW, Kletzmayr J, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000; 181:2063-6.
18. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.
19. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30:770-4.
20. Chang MH. Chronic hepatitis virus infection in children. J Gastroenterol Hepatol 1998; 13:541-8.
21. Lee PI, Chang MH, Lee CY, et al. Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. Hepatology 1990; 12:657-60.
22. Lok ASF, Chang MG, Watson G, et al. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998; 5:171-8.
23. Liaw YF. Chronic hepatitis B guidelines: east versus west. Hepatology 2002; 35:979-82.
24. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-75.
25. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33:963-71.
26. Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine treated hepatitis B patients [abstract 625]. Hepatology 1998; 28:319A.